Spine surgery cases grew about 20%, but Alphatec's revenue fell short of expectations.
Alphatec reported Q3 2026 revenue of $221M, up 13% YoY, but missed expectations due to lower biologics attachment. Surgical revenue grew 14% to $202M, with hardware revenue up 17%. Adjusted EBITDA expanded 400 basis points YoY. The company expects full-year revenue of approximately $880M and adjusted EBITDA of approximately $150M.
How this was made
The 30-second read
Why it matters
Traders should weigh strong procedural demand indicators against the specific revenue driver that missed expectations, and monitor management’s webcast Q&A for details on biologics attachment recovery and any updated full-year assumptions.
Market read
Company-specific earnings-style update with a clear stated revenue miss driver and management emphasis on improving biologics attachment.
What to watch
The article mentions a priority to improve biologics performance, but provides no quantified full-year guidance numbers in the scraped text, leaving uncertainty around how quickly attachment can recover.
Background
The piece summarizes Alphatec’s Q3 2026 results, including surgical case volume growth and a revenue miss attributed to biologics attachment.
Ticker impact
Alphatec reported Q3 case volumes up about 20% and said revenue missed expectations due to lower biologics attachment.
Likely downside pressure as investors focus on biologics attachment weakness versus the offsetting growth in cases and hardware.
The article attributes the revenue miss specifically to lower biologics attachment, which is a direct driver of revenue quality and near-term outlook.
Market effects
Highlights a key demand-to-revenue linkage in spine surgery workflows: procedural case growth may not translate to revenue if biologics attachment lags.
No clear regional spillover beyond US-listed medtech sentiment.
Limited; the disclosure is company-specific and does not indicate a broader global supply or regulatory shock.
Counterpoint
Hardware and case growth are strong, so the biologics attachment miss could be temporary execution or mix rather than a durable demand problem.
Key entities
- companyAlphatec
Spine surgery solutions provider reporting Q3 2026 results and attributing a revenue miss to lower biologics attachment.
- executivePat Miles
Chairman and CEO quoted on the biologics attachment shortfall and priority to improve performance.
- executiveTommy Carls
Joined senior leadership as EVP of Data Intelligence & Strategy, per the company’s highlights.
